Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Nixon

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 27, 2020
Human Immunodeficiency Virus-Experienced Clinician Workforce Capacity: Urban-Rural Disparities in the Southern United StatesRose S Bono, Bassam Dahman, Lindsay M Sabik, et al.
Journal of Clinical Lipidology|April 11, 2017
Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A5275)Daniel E Nixon, Ronald J Bosch, Ellen S Chan, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 17, 2012
HIV replication, inflammation, and the effect of starting antiretroviral therapy on plasma asymmetric dimethylarginine, a novel marker of endothelial dysfunctionJason V Baker, Jacqueline Neuhaus, Daniel Duprez, et al.
AIDS (London, England)|January 3, 2019
Associations between baseline biomarkers and lung function in HIV-positive individualsDavid M MacDonald, Alexander D Zanotto, Gary Collins, et al.
The Journal of Infectious Diseases|August 14, 2016
A Phase 1 Study of 4 Live, Recombinant Human Cytomegalovirus Towne/Toledo Chimera Vaccines in Cytomegalovirus-Seronegative MenStuart P Adler, Anne-Marie Manganello, Ronzo Lee, et al.
AIDS (London, England)|April 20, 2022
Cytomegalovirus viremia and risk of disease progression and death in HIV-positive patients starting antiretroviral therapyLaura I Levi, Shweta Sharma, Mark R Schleiss, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 9, 2010
Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infectionJason V Baker, Jacqueline Neuhaus, Daniel Duprez, et al.
Plos One|August 12, 2017
Sequence homology between HLA-bound cytomegalovirus and human peptides: A potential trigger for alloreactivityCharles E Hall, Vishal N Koparde, Maximilian Jameson-Lee, et al.
The Journal of Infectious Diseases|January 22, 2011
Plasma levels of soluble CD14 independently predict mortality in HIV infectionNetanya G Sandler, Handan Wand, Annelys Roque, et al.
The Lancet. Respiratory Medicine|October 25, 2016
Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trialKen M Kunisaki, Dennis E Niewoehner, Gary Collins, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 27, 2020
Human Immunodeficiency Virus-Experienced Clinician Workforce Capacity: Urban-Rural Disparities in the Southern United StatesRose S Bono, Bassam Dahman, Lindsay M Sabik, et al.
Journal of Clinical Lipidology|April 11, 2017
Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A5275)Daniel E Nixon, Ronald J Bosch, Ellen S Chan, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 17, 2012
HIV replication, inflammation, and the effect of starting antiretroviral therapy on plasma asymmetric dimethylarginine, a novel marker of endothelial dysfunctionJason V Baker, Jacqueline Neuhaus, Daniel Duprez, et al.
AIDS (London, England)|January 3, 2019
Associations between baseline biomarkers and lung function in HIV-positive individualsDavid M MacDonald, Alexander D Zanotto, Gary Collins, et al.
The Journal of Infectious Diseases|August 14, 2016
A Phase 1 Study of 4 Live, Recombinant Human Cytomegalovirus Towne/Toledo Chimera Vaccines in Cytomegalovirus-Seronegative MenStuart P Adler, Anne-Marie Manganello, Ronzo Lee, et al.
AIDS (London, England)|April 20, 2022
Cytomegalovirus viremia and risk of disease progression and death in HIV-positive patients starting antiretroviral therapyLaura I Levi, Shweta Sharma, Mark R Schleiss, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 9, 2010
Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infectionJason V Baker, Jacqueline Neuhaus, Daniel Duprez, et al.
Plos One|August 12, 2017
Sequence homology between HLA-bound cytomegalovirus and human peptides: A potential trigger for alloreactivityCharles E Hall, Vishal N Koparde, Maximilian Jameson-Lee, et al.
The Journal of Infectious Diseases|January 22, 2011
Plasma levels of soluble CD14 independently predict mortality in HIV infectionNetanya G Sandler, Handan Wand, Annelys Roque, et al.
The Lancet. Respiratory Medicine|October 25, 2016
Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trialKen M Kunisaki, Dennis E Niewoehner, Gary Collins, et al.
Pageof 3